Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341807 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
A Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations, sponsored by Spark Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT02341807: Completed Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations, sponsored by Spark Therapeutics.
NCT02341807 is a Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations that has completed, run by Spark Therapeutics. The registered enrollment target is 15 participants, below the 3,132-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02341807, a Phase 1 study of Choroideremia and CHM (Choroideremia) Gene Mutations, has completed, sponsored by Spark Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
Primary Outcome
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were AEs that occurred on or after the day of study drug administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Conditions Studied
Interventions
- BIOLOGICAL AAV2-hCHM
Study Locations (3)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Children's Hospital of Philadelphia - Philadelphia
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 1 |
What the finished NCT02341807 record still lists
NCT02341807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 3,132-participant average among 7 other Choroideremia trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Choroideremia appearing as the primary indexed condition, and to 1 intervention - of which AAV2-hCHM is the first listed.
NCT02341807 reports a single indexed study location in Pennsylvania, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02341807 about?
NCT02341807 is a clinical study titled "Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations". This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
What is the current status of trial NCT02341807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-01-15. Estimated completion is 2022-10-12.
What conditions does trial NCT02341807 study?
This clinical trial studies the following conditions: Choroideremia, CHM (Choroideremia) Gene Mutations.
What interventions are being tested in trial NCT02341807?
The interventions under investigation include: AAV2-hCHM (BIOLOGICAL).
Who is sponsoring clinical trial NCT02341807?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02341807 being conducted?
This trial has 3 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroideremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Natural Disease Progression in Participants With Choroideremia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI